Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 9INDUSTRY 3NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 2

Conditions

Neoplasms 79Lymphoma 63Breast Neoplasms 61Prostatic Neoplasms 60Multiple Myeloma 60Lung Neoplasms 55Neoplasm Metastasis 54Ovarian Neoplasms 47Leukemia, Myeloid, Acute 47Colorectal Neoplasms 41Hematologic Neoplasms 40Melanoma 39Carcinoma, Non-Small-Cell Lung 38Lymphoma, Non-Hodgkin 32Pancreatic Neoplasms 31Glioma 31Brain Neoplasms 30Urinary Bladder Neoplasms 28Myelodysplastic Syndromes 28Sarcoma 26Carcinoma, Renal Cell 26Glioblastoma 25Fallopian Tube Neoplasms 25Neuroblastoma 23Triple Negative Breast Neoplasms 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 22Stomach Neoplasms 19Small Cell Lung Carcinoma 19Squamous Cell Carcinoma of Head and Neck 18

Interventions

Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Hearing Loss × 1 year × Clear all
NCT04915183 2026-05-22

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT06303180 2025-11-14

NIDCD Otolaryngology Clinical Protocol Biospecimen Bank

National Institutes of Health Clinical Center (CC)

Recruiting
1,000 enrolled
Head & Neck

Head and Neck Neoplasms, Hearing Disorders, Laryngeal Diseases, Speech, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡